(Q33289264)

25 July 2017

1 reference

title

Time-series modeling of multiple sclerosis disease activity: a promising window on disease progression and repair potential? (English)

1 reference

25 July 2017

2

Howard L Weiner

1 reference

25 July 2017

3

Charles R G Guttmann

1 reference

25 July 2017

Dominik S Meier

1

1 reference

25 July 2017

publication date

1 July 2007

1 reference

25 July 2017

1 reference

25 July 2017

volume

4

1 reference

25 July 2017

issue

3

1 reference

25 July 2017

page(s)

485-498

1 reference

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

25 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.05.008

Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.05.008

Cortical demyelination and diffuse white matter injury in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.05.008

Immunopathology of secondary-progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.05.008

Whole brain volume changes in patients with progressive MS treated with cladribine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.05.008

The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.05.008

Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.05.008

Is late-onset multiple sclerosis associated with a worse outcome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.05.008

Baseline MRI predicts future attacks and disability in clinically isolated syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.05.008

The longitudinal relation between brain lesion load and atrophy in multiple sclerosis: a 14 year follow up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.05.008

Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.05.008

Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.05.008

Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.05.008

Significance of T2 lesions in multiple sclerosis: A 13-year longitudinal study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.05.008

MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.05.008

Longitudinal brain volume measurement in multiple sclerosis: rate of brain atrophy is independent of the disease subtype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.05.008

Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.05.008

Magnetization transfer MRI metrics predict the accumulation of disability 8 years later in patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.05.008

Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.05.008

Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.05.008

Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.05.008

A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis. Implications for phase II clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.05.008

Is inflammation important in early PPMS? a longitudinal MRI study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.05.008

Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.05.008

Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. European Study Group on Interferon-beta1b in secon

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.05.008

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.05.008

Quantitative assessment of MRI lesion load in monitoring the evolution of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.05.008

Defining multiple sclerosis disease activity using MRI T2-weighted difference imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.05.008

Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.05.008

Time-series analysis of MRI intensity patterns in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.05.008

MRI time series modeling of MS lesion development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.05.008

A quantitative analysis of oligodendrocytes in multiple sclerosis lesions. A study of 113 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.05.008

Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.05.008

Remyelination is extensive in a subset of multiple sclerosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.05.008

Protective autoimmunity and neuroprotection in inflammatory and noninflammatory neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.05.008

Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes".

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.05.008

A Longitudinal Study of Abnormalities on MRI and Disability from Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2007.05.008

Multiple sclerosis: A serial study using MRI in relapsing patients

21 January 2018

1 reference

12 December 2020

Serial magnetic resonance imaging in multiple sclerosis: correlation with attacks, disability, and disease stage

1 reference

12 December 2020

Serial magnetic resonance scanning in multiple sclerosis: a second prospective study in relapsing patients

1 reference

12 December 2020

The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course

1 reference

12 December 2020

Changes in activated T cells in the blood correlate with disease activity in multiple sclerosis

1 reference

12 December 2020

Resolution-dependent estimates of multiple sclerosis lesion loads

1 reference

12 December 2020

Patterns of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization transfer MR.

1 reference

12 December 2020

Patterns of enhancing lesion evolution in multiple sclerosis are uniform within patients

1 reference

12 December 2020

Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability

1 reference

12 December 2020

Recent neuropathological findings in MS--implications for diagnosis and therapy

1 reference

12 December 2020

Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in

1 reference

12 December 2020

A longitudinal MRI study of histopathologically defined hypointense multiple sclerosis lesions

1 reference

12 December 2020

Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group

1 reference

12 December 2020

10.1016/J.NURT.2007.05.008

Identifiers

DOI

1 reference

Dimensions Publication ID

25 July 2017

1050848095

0 references

PMC publication ID

7479736

0 references

1 reference